Pressure BioSciences, Inc. announced that the Company’s largest shareholder has exchanged over $10 million of senior secured debt into unsecured preferred stock. The debt being converted is comprised of convertible promissory notes, accrued and unpaid interest on all promissory notes issued to...

Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced the signing of an exclusive worldwide license agreement (the “License Agreement”) with the ...

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that its GMP packaged OK-101 drug to be used in t...

OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announces the appointment of Jay S. Pepose, M.D., Ph.D., Founder and...

Laser Photonics Corporation (NASDAQ: LASE) (“LPC”), a leading global developer of industrial CleanTech laser systems for laser cleaning and other materials applications, today announced it recently received an annual approval by the Center for Devices and Radiological Health (CDHR) and the Fo...

Amesite, a Michigan-based EdTech company, has announced that it will be integrating OpenAI's GPT-3 technology into its platform. This integration will allow Amesite to deliver personalized learning experiences to its users by leveraging GPT-3's advanced natural language processing capabilities.

Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform that delivers 99% learner retention for business and education markets, announced an expansion of platform capabilities today.